Introduction
Stroke is a common and devastating event, which often results in death or major loss of independence with immense human and financial costs. It is the third most common cause of death in most Western populations after coronary heart disease and cancer (Warlow et al, 1996) . The majority of strokes are not fatal, and the major burden is long-term disability. It is therefore the most important single cause of severe disability among Western people living in their own homes (Martin & Elliot, 1998) . Stroke in the developing world is less well documented. A statement from the AsiaPacific Consensus Forum on Stroke Management predicts that 'In the next 30 years or so the burden of stroke will grow most in developing countries rather than in the developed world' (Poungvarin, 1998) .
There is strong indirect evidence that free radical production is an important mechanism of brain injury after exposure to ischaemia and reperfusion (Traystman et al, 1991) .
Animal models of transient ischaemia/reperfusion in the brain suggest that brain lipids are vulnerable to oxidative attack with accumulation of both conjugated dienes and thiobarbiturate-reactive material during this period (Traystman et al, 1991) . This effect is enhanced by poor a-tocopherol (vitamin E) and ascorbic acid (vitamin C) status (Cooper et al, 1980) , and can be mitigated by supplementation with vitamin E (Yoshida et al, 1984) . Recent studies in humans have reported an association between the plasma concentration of ascorbic acid and a-tocopherol and early clinical outcome after acute ischaemic stroke (Cherubini et al, 2000; Leinonen et al, 2000) . A study by Leinonen et al (2000) reported an association between the plasma concentration of ascorbic acid and a-tocopherol and the degree of neurological impairment after ischaemic stroke . Cherubini et al (2000) also found evidence of reduced plasma antioxidant concentrations in ischaemic stroke patients and that higher plasma vitamin A and uric acid concentrations and lower plasma ascorbic acid concentrations and erythrocyte superoxide dismutase activity were associated with poor early clinical outcome. There is also some recent evidence of an association between oxidative damage and tissue inflammation as measured by C-reactive proteins (CRPs) in subjects with stroke disease (Gariballa et al, 2002) . In the same study, we found deterioration in antioxidant capacity following acute stroke within a known period of time postinfarct. The aim of this study was, therefore, to test whether supplementary antioxidants during the acute period following acute ischaemic stroke enhances antioxidant capacity and mitigates oxidative damage.
Subjects and methods

Subject recruitment
For a 9-month period all patients admitted to a University Teaching Hospital with a diagnosis of ischaemic stroke according to the World Health Organization criteria were identified prospectively and suitable subjects were recruited into a randomised controlled study. After informed consent 48 acute ischaemic stroke patients admitted within 12 h of symptom onset (excluding those with cerebral or subarachnoid haemorrhage on CT head scan) were assigned to receive oral supplementation of 800 IU (727 mg) a-tocopherol and 500 mg vitamin C (n ¼ 24) daily, or no supplementation (n ¼ 24) for 14 days. All patients, however, received standard medical treatment for acute stroke. No subject received thrombolytic therapy. Stroke patients with active gastrointestinal disease, severe concurrent medical illness such as sepsis or acute renal failure, history of gout, supplemental vitamins, bleeding disorders or inability or refusal to give consent were excluded. Subjects with psychiatric disorders were also excluded. Treatment group and controls were matched for age and stroke subtype. The classification of stroke was based on clinically identifiable subtypes of cerebral infarction as described by Bamford et al (1991) . This classification is said to have important prognostic implications and is useful for planning stroke treatment trials. The classification is based on anatomical circulation: large anterior circulation infarcts with both cortical and subcortical involvement (total anterior circulation infarcts, TACI); more restricted and predominantly cortical infarcts (partial anterior circulation infarcts, PACI); infarcts associated with the vertebro-basilar arterial territory (posterior circulation infarcts, POCI) and infarcts confined to the territory of the deep perforating arteries (lacunar infarcts, LACI).
Protocol
Nonfasting venous blood was obtained before treatment (within 12 h of stroke onset) and at day 7 and day 14. Blood was collected in appropriate tubes and, following separation from red blood cells; plasma was stored at À701C for analysis within 12 weeks. All analyses were performed blind to the identity of the sample. Plasma a-tocopherol was measured by high-performance liquid chromatography (Thurnham et al, 1988) and plasma total ascorbic acid by a fluorescence assay automated for the Cobas BioAutoanalyser (Vuilleumier, 1989) , giving interbatch cv's of 4.3 and 9.0%, respectively. Total antioxidant capacity (TAOC) was measured as the ability of plasma to inhibit free-radical-induced oxidation in an assay automated for the Cobas BioAutoanalyser and with an interbatch cv of 5.0% (Miller et al, 1993) . Serum cholesterol concentrations measured by a cholesterol oxidase assay using the Beckman Synchron LX System (Kit number 467825) were used to adjust a-tocopherol values. The interbatch cv of this assay was 6.0%. plasma malondialdehyde (MDA), a marker of lipid peroxidation, was also measured by high-performance liquid chromatography using fluorescence detection (Wong et al, 1987) , and this runs with an interbatch cv of 9.0%. Plasma CRP concentration, a marker of acute inflammation in stroke (Di Napoli et al, 2001 ) and other illnesses (normal range o6 mg/l), was measured at baseline, day 7, 14 and 90 by a modified latex enhanced immunoturbidimetric assay (Beckman Synchron LX System, Kit number 465131). Plasma uric acid concentration was measured by an enzymatic uricase fluorescence method (normal range 160-400 mmol/l) on the Beckman Synchron LX System (Kit number 442785). The interbatch cv's for these assays were 6.5 and 5.0%, respectively.
All patients had demographic and medical data collected at baseline including history of hypertension, smoking, alcohol and drug intake, diabetes mellitus, and cardiovascular diseases. They were also followed up during the hospital stay and at 3 months postrecruitment for clinical infections and reinfarctions. Disability was assessed prospectively using the Barthel score on a 100-point scale (Standardised assessment scales for older people, 1992). The Barthel scores 10 functions on a scale 0 (fully dependent) to 100 (independent).
Allocation of treatment
The method of minimisation is an accepted form of randomisation (Pocock, 1988) and was chosen because it minimises any differences and provides treatment groups very similar for major prognostic variables. The effect of this procedure was that the groups were more or less similar with regard to the chosen variables of interest. In this trial the following variables were used for minimisation: 1. Clinical stroke subtype (TACI, PACI, LACI, POCI) 2. Age (o75, Z75 y)
Sample size calculation A previous study has shown that daily supplements of 400 mg vitamin C and 200 mg vitamin E to healthy male smokers for 3 months increased plasma concentrations of ascorbic acid and a-tocopherol by 45 and 72%, respectively (Nyyssonen et al, 1994) . A sample size of 48 ischaemic stroke patients (24 treatment group þ 24 controls) allows the detection of a 40% difference between groups in plasma ascorbic acid and/or plasma a-tocopherol concentrations with 80% power and type 1 error probability of r0.05.
Data analysis
Statistical analyses were performed with SPSS software, version 11.0 (SPSS Inc., Chicago, USA). Descriptive tests were used to test data distribution and standard errors. Most variables were skewed hence the use of nonparametric tests. Kruskall-Wallis test and Mann-Whitney U-test were used where appropriate. Differences between groups at baseline were adjusted for history of smoking and alcohol consumption, chronic illness, drug intake (aspirin, angiotensin-converting enzyme inhibitors, beta-blockers, calcium channel blockers, diuretics and nitrates) and plasma CRP concentration. Differences in CRP concentrations between treatment and control group were adjusted for clinical infections and reinfarctions. Forward stepwise multiple regression analysis was performed to determine the predictive importance of baseline variables (age, stroke subtype, drugs, chronic disease and CRP) for plasma TAOC and MDA. Adjusted and change in R 2 values were then used to measure the extent to which the TAOC and MDA concentrations could be explained by individual antioxidants (vitamin C, vitamin E and uric acid) and other clinical variables included in the model. Results were considered significant when the P-value was o0.05. The study was approved by the Local Health Ethics Committee and all subjects or their carers gave informed consent. Table 1 shows baseline characteristics of treatment group and controls on entry into the study. The two groups were comparable with respect to age, clinical stroke subtype, chronic disease, drug and alcohol intake and time between stroke onset and randomisation (P40.05). Although the control group subjects were older, more disabled and had higher serum creatinine concentration and prevalence of atrial fibrillation compared with the treatment group these baseline differences did not reach statistical significance.
Results
Vitamin supplements were prescribed in patients' drug cards and compliance for surviving patients was 100%, with no treatment failure or withdrawal.
In all, 14 days of vitamin supplementation increased cholesterol-corrected plasma a-tocopherol and ascorbic acid concentrations in the treatment group compared with the control group (Table 2) . Plasma TAOC and MDA concentrations and changes during the study period are shown in Table 3 . TAOC increased in the treatment group in contrast with controls and the difference between groups was significant. There was a reduction in plasma MDA concentration in the treatment group, in contrast to the increase seen in the control group and these changes were also significantly different. These changes were most marked during the first week of the study. However, the difference between day 0-14 in both TAOC and MDA was not statistically significant.
In a multivariate analysis of all subjects serum uric acid explained most of the variance in TAOC during the study period. Of the other analytes included in the multivariate model only stroke subtype showed significant correlation with TAOC at day 7 (Table 4) . On the other hand, most of the variance in MDA was explained by plasma a-tocopherol at days 7 and 14, while age showed significant correlation with MDA at baseline and day 14 (Table 5) . Figure 1 shows the CRP profile over a period of 3 months following the stroke. CRP concentrations were significantly lower in the supplement group compared with controls following treatment. There were no differences between the treatment group and controls in incidence of clinical infections (pneumonia, urinary tract infection and septicaemia) or reinfarctions. For example, during the first and second week of the trial rates of infection in the antioxidant group were 4.2 and 12.5%, respectively, compared with 12.5 and 4.2% in the control group. One patient in the treatment group had cerebral reinfarction compared with two in the treatment group.
Discussion
Supplementation with antioxidant vitamins within 12 h postinfarct after acute stroke increased plasma antioxidant capacity and reduced lipid peroxidation products. However, differences in TAOC and MDA were only significant during the first week. This occurred in association with a predicted increase in the plasma concentration of ascorbic acid and a-tocopherol.
Plasma CRP was also lower in those stroke patients who received antioxidant supplements compared with controls at 7 and 14 days. There is evidence that free radical production is an important mechanism of brain injury after exposure to ischaemia and reperfusion (Traystman et al, 1991) . While it is not possible to make direct measurements of antioxidant activity and oxidant damage in this target tissue, concentrations of antioxidants and products of oxidative damage in plasma have proved informative in other studies of stroke (Cherubini et al, 2000; Leinonen et al, 2000) .
A recent uncontrolled study of 22 ischaemic stroke patients reported an association between the plasma concentration of ascorbic acid and a-tocopherol and the degree of neurological impairment after ischaemic stroke (Leinonen et al, 2000) . The same study demonstrated an association between plasma total antioxidant activity and the volume of ischaemic cerebral infarction and the degree of subsequent neurological impairment. Another study of 38 ischaemic stroke patients and age and sex-matched controls reported reduced plasma antioxidant concentrations in stroke patients compared with controls and showed an association between poor antioxidant status and poor clinical outcome (Cherubini et al, 2000) . Furthermore, Polidori et al (1998) reported a significant positive association between plasma lipid hydroperoxide concentration and the National Institute of Health Stroke Scale, and a significant negative correlation with the Glasgow Coma Scale (Polidori et al, 1998) .
A particular benefit from supplementing with vitamin C and E simultaneously is considered to derive from the interaction of these vitamins in cellular metabolism. aTocopherol is found mainly in the lipid compartment of cells and extracellular fluid, whereas ascorbic acid is located in the aqueous compartments. However, in vitro, and recently, in vivo studies point to an interaction such that there may be a mutual 'sparing' effect (Hamilton et al, 2000) . Ascorbic acid appears to be able to regenerate the reduced, antioxidant form of a-tocopherol through redox cycling (May et al, 1998) . A number of clinical trials have been published recently regarding the effects of vitamin antioxidants supplementation on the risk of cardiovascular diseases including stroke (Gariballa, 2004; Heart Protection Study Collaborative Group, 2002; Tornwall et al, 2004) . The overall results of these clinical trials were somewhat disappointing given the consistent and promising findings from epidemiological studies and the strength of the evidence for the oxidative modification hypothesis in cardiovascular diseases. One explanation for this paradox is that animal intervention evidence on which these trials were based deals primarily with very early lesions. Antioxidants are reducing agents, which act by scavenging damaging oxidising agents such as free radicals. Transitional-metal ions, which are released as a result of injury by oxidative damage, act as catalysts of free radical damage, especially in the reduced state. If for example, a powerful antioxidant (ie, powerful reducing agent) is administered after oxidative damage has started this could promote damage. Therefore, administration of antioxidants can give protective effects or worsen damage depending on where one in the sequence of events. Future human trials may need to take into account the severity of oxidative damage and maturity of atherosclerotic lesions, in order to test whether antioxidants can decrease the rate of initiation and early progression of atherosclerosis as they do in animals (Gariballa, 2004) . It should be noted that our study treatment was commenced within a short period following the stroke.
Elevated plasma CRP concentration during the acute phase of recovery in stroke is independently predictive of poor long-term outcome (Muir et al, 1999; Winbeck et al, 2002) . There is some evidence that, in subjects with atherosclerotic disease, supplementation with vitamins C and E reduces plasma CRP. Devaraj and Jialal demonstrated that 3 months of vitamin E supplementation significantly lowered levels of CRP and monocyte interleukin-6 in diabetic subjects with macrovascular disease and also in healthy controls (Devaraj & Jialal, 2000) . Low plasma concentrations of ascorbic acid have been inversely correlated with plasma CRP concentrations and severity of atherosclerotic disease (Langlois et al, 2001 ). Although we have adjusted for some important prognostic variables such as the nature of cerebral infarction and secondary complications in our study it is impossible to exclude other subclinical causes for the differences in CRP concentrations.
In a recent study, we reported that plasma concentrations of ascorbic acid fell significantly over two weeks following the stroke and that ischaemic stroke patients had lower plasma TAOC than non-stroke controls. In addition, TAOC was strongly correlated with serum uric acid concentrations (Gariballa et al, 2002) . In the present study uric acid explained most of the variance in TAOC during the study period. Uric acid, which is the end product of purine metabolism, has long been regarded as a potent endogenous water-soluble antioxidant and radical scavenger in human (Patt et al, 1988) .
Overall and in the light of the strong scientific evidence which links free radical-induced oxidative stress and pathogensis of ischaemic stroke, the significant improvement in markers of antioxidant capacity, oxidative damage and tissue inflammation, these findings may potentially be very important and need to be explored further in future research. One potential limitation in our study was that investigators were not blinded as to the treatment vs nontreatment group. However, all biochemical measurements were performed blind to the groups in the study.
In conclusion, we have demonstrated that supplementation with antioxidants within 12 h postinfarct after acute stroke increases plasma antioxidant capacity and reduces plasma lipid peroxidation products and markers of acute inflammation (CRP). If these results translate into clinical measurable benefit in stroke disease, this simple treatment is likely to have considerable public health implications. Future large studies with clinical end points are therefore needed to explore the potential therapeutic benefit of early antioxidant intervention following acute ischaemic stroke.
